Monopar Therapeutics Inc. has reported its third quarter financial results for 2026, revealing a net loss increase compared to the same period last year. The company, which focuses on developing innovative treatments for unmet medical needs, continues to make strides in its drug development programs, particularly for Wilson disease.
On November 12, 2026, Monopar announced its financial results for the third quarter ended September 30, 2026. According to the filing, the company reported a net loss of $6.2 million, or $0.72 per share, compared to a net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025. Cash, cash equivalents, and investments totaled $129.4 million as of September 30, 2026, which the company expects will support operations through at least March 31, 2028.
Monopar Therapeutics, classified under SIC code 2834 for Pharmaceutical Preparations, is a clinical-stage biopharmaceutical company headquartered in Wilmette, Illinois. The company trades on the Nasdaq under the ticker MNPR. It is focused on developing treatments that address significant unmet medical needs, particularly through its lead drug candidate, ALXN1840, aimed at treating Wilson disease.
The recent filing included a press release detailing the company’s ongoing drug development efforts. Notably, on November 8, 2026, Monopar presented findings from the Phase 3 FoCus study of ALXN1840 at the American Association for the Study of Liver Diseases. This study is significant as it is the largest randomized controlled trial conducted in Wilson disease, highlighting the burden of the disease in treatment-experienced patients.
In the press release, Monopar highlighted that baseline findings showed high rates of cirrhosis and neurological symptoms in both treatment-experienced and treatment-naïve patients. The company also reported that only 47% of treatment-experienced patients were within the guideline-recommended copper target range, illustrating the challenges faced in managing this disease.
Monopar's R&D expenses for the third quarter of 2026 were reported at $4.4 million, a significant increase from $2.6 million in the same quarter of 2025. This rise in expenses is attributed to increased contractor and consulting fees, as well as personnel costs associated with the ongoing development of its drug candidates.
The filing indicates that Monopar is on track to complete the New Drug Application (NDA) submission for ALXN1840 within the next several weeks, following a rolling submission approved by the FDA. This strategic move allows the company to submit completed sections of the application for review while finalizing the remaining parts.
As Monopar continues to advance its clinical programs, the company remains committed to addressing the needs of patients suffering from Wilson disease and other unmet medical conditions. The financial results and updates provided in this filing may have implications for investors and stakeholders as they evaluate the company's path forward.
The next steps for Monopar Therapeutics are not detailed in the filing, but the company is expected to continue its efforts in drug development and regulatory submissions. Investors and industry observers will be keen to follow the company’s progress as it navigates the complexities of bringing new therapies to market.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










